Skip to main
IMCR
IMCR logo

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 33%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 6%

Bulls say

Immunocore Holdings PLC is positioned favorably in the biotechnology sector, supported by its ImmTAX platform that is generating a deep pipeline across multiple therapeutic areas including oncology and infectious diseases. The company's lead product, KIMMTRAK, has shown significant survival benefits in metastatic uveal melanoma, alongside strong early sales and market penetration, which contribute to a positive revenue outlook. Additionally, the potential advancements in HIV treatment with drug candidates such as IMC-M113V further reinforce a bullish perspective on Immunocore's capability in developing innovative therapies.

Bears say

Immunocore Holdings PLC faces several challenges that contribute to a negative outlook on its stock. The company's bear case assumptions indicate a lack of observed clinical benefit for key programs, including IMC-F106C, leading to significantly reduced positive outcomes in critical indications such as PROC and NSCLC, thereby implying potential downside risks to its projected financial metrics. Additionally, the company's efforts in developing successful clinical candidates outside its established ImmTAC, ImmTAV, and ImmTAI platforms are complicated by treatment safety, scalability, and accessibility issues associated with complex diseases like HIV, which poses substantial obstacles to generating meaningful returns from its pipeline.

Immunocore Holdings (IMCR) has been analyzed by 18 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 18 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.61, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.61, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.